Afluria Injection, Suspension
NDC Package 33332-025-03

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. NDC HCPCS Crosswalk
    3. Frequently Asked Questions

Package Information

This product is approaching its end of marketing date. An upcoming end of marketing date means the product has been delisted but will remain in the NDC database until the end of marketing date is reached. In most cases, the FDA advises firms to use the expiration date of the last lot produced as the end marketing date, reflecting the possibility that the product may still be available even after manufacturing has stopped.

Afluria (influenza a virus a/victoria/4897/2022 ivr-238 (h1n1) antigen (propiolactone inactivated), influenza a virus a/croatia/10136rv/2023 x-425a (h3n2) antigen (propiolactone inactivated), influenza b virus b/austria/1359417/2021 bvr-26 antigen (propiolactone inactivated)) injection is aFLURIA® is an inactivated influenza vaccine indicated for active immunization for the prevention of disease caused by influenza A subtype viruses and type B virus contained in the vaccine. This formulation utilizes a injection, suspension delivery system. Marketed by Seqirus Pty Ltd., this product is identified by NDC 33332-025 and is authorized under FDA application BLA125254.

Identification & Billing

NDC Package Code
33332-025-03
Package Description
10 SYRINGE, GLASS in 1 CARTON / .5 mL in 1 SYRINGE, GLASS (33332-025-04)
Product Code
33332-025
11-Digit Billing Format
33332002503
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
RxNorm Crosswalk
  • RxCUI: 2718386 - influenza virus vaccine 2025-2026 (trivalent - Croatia/Victoria/Austria) 0.5 ML Prefilled Syringe
  • RxCUI: 2718386 - 0.5 ML influenza A virus A/Croatia/10136RV/2023 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/4897/2022 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Austria/1359417/2021 antigen 0.03 MG/ML Prefilled Syringe
  • RxCUI: 2718400 - afluria 2025-2026 vaccine 0.5 ML Prefilled Syringe
  • RxCUI: 2718400 - 0.5 ML influenza A virus A/Croatia/10136RV/2023 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/4897/2022 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Austria/1359417/2021 antigen 0.03 MG/ML Prefilled Syringe [Afluria 2025-2026]
  • RxCUI: 2718400 - Afluria 2025-2026 vaccine 0.5 ML Prefilled Syringe

Clinical Specifications

Proprietary Name
Afluria
Non-Proprietary Name
Influenza A Virus A/victoria/4897/2022 Ivr-238 (h1n1) Antigen (propiolactone Inactivated), Influenza A Virus A/croatia/10136rv/2023 X-425a (h3n2) Antigen (propiolactone Inactivated), Influenza B Virus B/austria/1359417/2021 Bvr-26 Antigen (propiolactone Inactivated)
Substance Name
Influenza A Virus A/croatia/10136rv/2023 X-425a (h3n2) Antigen (propiolactone Inactivated); Influenza A Virus A/victoria/4897/2022 Ivr-238 (h1n1) Antigen (propiolactone Inactivated); Influenza B Virus B/austria/1359417/2021 Bvr-26 Antigen (propiolactone Inactivated)
Dosage Form
Injection, Suspension - A liquid preparation, suitable for injection, which consists of solid particles dispersed throughout a liquid phase in which the particles are not soluble. It can also consist of an oil phase dispersed throughout an aqueous phase, or vice-versa.
Administration Route
Intramuscular - Administration within a muscle.
Active Ingredient(s)
Usage Information
AFLURIA® is an inactivated influenza vaccine indicated for active immunization for the prevention of disease caused by influenza A subtype viruses and type B virus contained in the vaccine. AFLURIA is approved for use in persons 6 months of age and older.

Regulatory & Marketing

Labeler Name
Seqirus Pty Ltd.
Product Type
Vaccine
FDA Application #
BLA125254
Marketing Category
BLA - A product marketed under an approved Biologic License Application.
Start Marketing Date
07-01-2025
End Marketing Date
07-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Billing & HCPCS Mapping

To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.

90656
Source: AWP
IIV3 VACC NO PRSV 0.5 ML IM
HCPCS Dosage 0.5 ML
Units / Pkg 10

Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 33332-025-03 identifies a specific commercial package of 10 syringe, glass in 1 carton / .5 ml in 1 syringe, glass (33332-025-04) of Afluria, a vaccine label labeled by Seqirus Pty Ltd.. This injection, suspension is formulated for intramuscular use and contains influenza a virus a/croatia/10136rv/2023 x-425a (h3n2) antigen (propiolactone inactivated); influenza a virus a/victoria/4897/2022 ivr-238 (h1n1) antigen (propiolactone inactivated); influenza b virus b/austria/1359417/2021 bvr-26 antigen (propiolactone inactivated) as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Seqirus Pty Ltd. on July 01, 2025.

How is this Seqirus Pty Ltd. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 33332002503. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
33332-025-03
11-Digit CMS (5-4-2)
33332-0025-03

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.